OnCo
key papersKey paper

Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma

Blocking the immune brake CTLA-4 was the first treatment ever to prolong life in metastatic melanoma, with about one in five patients alive at two years and a new class of autoimmune side effects.

This phase 3 trial randomised 676 patients with previously treated, HLA-A*0201-positive metastatic melanoma in a 3:1:1 ratio to ipilimumab plus a gp100 peptide vaccine, ipilimumab alone, or gp100 alone. The primary endpoint was overall survival. Median OS was 10.0 months with ipilimumab plus gp100 and 10.1 months with ipilimumab alone versus 6.4 months with gp100 (hazard ratios 0.68 and 0.66), with survival curves showing a durable tail. Grade 3-4 immune-related adverse events occurred in 10-15% of ipilimumab-treated patients, and 14 deaths were related to study drugs, 7 from immune-related events. It led to FDA approval in March 2011 and validated James Allison's checkpoint-blockade hypothesis in humans.

Randomised controlled trialChanged practice676 participants
Authors
Hodi FS, O'Day SJ, McDermott DF, et al.
What it found
  • 676 previously treated metastatic melanoma patients; ipilimumab + gp100, ipilimumab alone, or gp100 alone (3:1:1).
  • Median OS 10.0 and 10.1 months with ipilimumab arms vs 6.4 months with gp100; hazard ratios 0.68 and 0.66.
  • Response rates were low (about 11% for ipilimumab alone) yet survival improved, showing a disconnect between shrinkage and benefit.
  • Grade 3-4 immune-related adverse events 10-15% with ipilimumab; 7 deaths from immune-related events.
  • A plateau in the survival curve suggested long-term survivors, later confirmed at about 20% alive at 3 years in pooled analyses.
What it means

This paper launched the immunotherapy era. It was the first randomised evidence that taking a brake off the immune system could extend life in a solid cancer, and it introduced clinicians to immune-related adverse events and to responses that arrive late or after apparent progression. Ipilimumab alone has since been superseded by PD-1 antibodies and combinations, but every checkpoint programme traces back to this result.

Be careful
  • Comparator was a peptide vaccine, not an active therapy, and was itself of uncertain effect.
  • Restricted to HLA-A*0201-positive patients because of the vaccine.
  • Response rate was low; benefit concentrated in a minority with durable responses.
  • Toxicity was substantial and management was still being learned.

Key papers

3top
rctNew England Journal of Medicine 2025changed practice
CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later

Before 2011 median survival in metastatic melanoma was under a year; this trial shows that roughly half of patients treated with combination checkpoint blockade are now long-term survivors, effectively cured. It anchors first-line treatment of advanced melanoma and sets the benchmark for every new regimen, including nivolumab-relatlimab. The combination's toxicity means nivolumab alone or newer doublets remain reasonable for some patients.

guidelineJournal of Clinical Oncology 2021changed practice
ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors

Checkpoint inhibitors are now given to hundreds of thousands of patients a year, many in community clinics and emergency departments, so a common, explicit playbook for their autoimmune side effects saves lives. The guideline standardised when to stop, when to give steroids and when to escalate, and made multidisciplinary toxicity teams routine. It does not remove the judgement needed for rare events or for patients whose cancer is responding.

translationalNew England Journal of Medicine 2012changed practice
Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer

This study is why PD-1 inhibitors were developed across cancers rather than in melanoma alone: unexpected activity in lung cancer, historically thought immune-resistant, changed drug development priorities industry-wide. It also introduced PD-L1 immunohistochemistry as a candidate biomarker and pneumonitis as a signature toxicity. Within five years PD-1 blockade was approved in more than ten cancers.

Connected

16top

Pages like this

not linked directly; found by shared links